Article

Fourth-generation quinolones standard of care for cataract surgery endophthalmitis prophylaxis

New Orleans-When selecting a topical antibiotic for endophthalmitis prophylaxis in cataract surgery, consideration should be given only to one of the newer generation fluoroquinolones, either moxifloxacin 0.5% (Vigamox, Alcon Laboratories) or gatifloxacin 0.3% (Zymar, Allergan), said Francis S. Mah, MD.

"For some years, fluoroquinolones have been the standard topical antimicrobial agents used in ophthalmology. However, the previous generation fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin) have lost much of their initial potency, and we feel they should be replaced with the newer products, which offer increased antibacterial potency, including against the gram-positive bacteria that are the most important pathogens in endophthalmitis, as well as improved penetration into the anterior chamber," said Dr. Mah, assistant professor of ophthalmology, Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh.

To study whether a newer-generation topical fluoroquinolone could effectively eradicate bacterial pathogens in the anterior chamber and prevent endophthalmitis, Dr. Mah and colleagues tested the efficacy of moxifloxacin in a rabbit model of endophthalmitis. Animals received an intraocular challenge with 5x104 colony-forming unites of a clinical isolate of Staphylococcus aureus. One group of animals received moxifloxacin drops every 15 minutes for 1 hour prior to the challenge and for four more doses over the next 24 hours. A control group was treated at the same intervals with saline.

Slit-lamp observations from an ophthalmologist masked to treatment assignment showed that at 24 hours after inoculation, no animals treated with moxifloxacin developed endophthalmitis whereas all of the saline-treated control eyes had clinical evidence of disease.

"This published study provides proof of principle that topical treatment with this fourth-generation fluoroquinolone pre- and postintraocular bacterial challenge could prevent bacterial endophthalmitis," said Dr. Mah.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.